红乳房综合征综述:文献系统性回顾与单中心病例系列
该定性系统综述汇总PubMed和Scopus文献,聚焦脱细胞真皮基质(ADM)乳房再造后红乳房综合征(RBS)的病因、表现、诊断和治疗。RBS发生率0%至29.6%,局部红斑、炎症标志物正常、抗生素无效,皮质类固醇最有效。单中心8例RBS在术后4周至7个月发病,激素或保守治疗数日至数周缓解。
要点
- RBS发生率0%至29.6%,表现为ADM区域局部红斑,炎症标志物正常。
- 抗生素治疗常无效,皮质类固醇是最一致有效的治疗。
- 部分病例需移除或更换ADM,需与手术部位感染鉴别。
核心结论
- RBS是ADM乳房再造后不常见的炎症并发症,临床可模仿手术部位感染。
- 皮质类固醇是最一致有效的治疗,部分病例需移除或更换ADM。
研究设计与样本
- 定性系统综述,检索PubMed和Scopus,纳入29项研究(病例报告、病例系列、回顾或前瞻性队列研究)。
主要发现
- RBS报告发生率范围为0%至29.6%。
- 多数报告描述红斑局限于ADM区域,炎症标志物正常,影像学阴性,抗生素治疗常无效。
- 单中心8例症状出现于术后4周至7个月,炎症标志物正常,影像学罕见积液,皮质类固醇或保守治疗数日至数周缓解。
关键数值与推荐
- RBS发生率0%至29.6%。
- 单中心病例系列n=8,症状出现于术后4周至7个月。
临床怎么用
- 对ADM乳房再造后局部红斑、炎症标志物正常、抗生素无效者应怀疑RBS。
- 皮质类固醇可作为RBS的治疗选择,部分病例需移除或更换ADM。
局限性
- 证据多来自病例报告和病例系列,需前瞻性研究及制造商层面内毒素检测以阐明发病机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Red breast syndrome (RBS) is an uncommon inflammatory complication that may occur following implant-based breast reconstruction and can clinically mimic surgical-site infection. This qualitative systematic review, based on comprehensive PubMed and Scopus searches, summarizes the existing literature on RBS, focusing on its etiology, clinical presentation, diagnostic characteristics, and therapeutic approaches following breast reconstruction using acellular dermal matrices (ADMs). A management protocol is proposed based on available data, and a single-center case series is presented from our Hospital, including patients who developed RBS after direct-to-implant reconstruction with ADM between January 2022 and December 2024. Twenty-nine studies met the inclusion criteria, comprising case reports, case series, and retrospective or prospective cohort studies. The reported incidence of RBS ranged from 0% to 29.6%. Proposed etiologies include endotoxin contamination, residual cellular debris, delayed hypersensitivity reactions, and lymphatic or vascular impairment of mastectomy flaps. Most reports described localized erythema confined to the area of the ADM, with normal inflammatory markers and negative imaging findings, whereas antibiotic therapy frequently failed to achieve improvement. Corticosteroids represented the most consistently effective treatment, although some cases required ADM removal or replacement. In our institutional case series (n = 8), symptom onset occurred between 4 weeks and 7 months postsurgery. Inflammatory markers remained within normal limits, imaging rarely demonstrated fluid collections, and symptoms resolved within days to weeks with corticosteroid therapy or conservative management. This review consolidates current evidence, proposes a diagnostic-therapeutic algorithm and highlights the need for prospective investigations and manufacturer-level endotoxin testing to elucidate pathogenesis and optimize clinical management. Level of Evidence: 2 (Risk) For image description, please refer to the figure legend and surrounding text.
引用
- Zanetti E, Quaglia D, De Francesco F, et al. An Overview of Red Breast Syndrome: A Qualitative Systematic Review of the Literature and a Single-Center Case Series. Aesthet Surg J. 2026. PMID: 41784074. doi:10.1093/asj/sjag053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。